Recent observations indicate prostatic diseases are comorbidities of systemic metabolic dysfunction. These discoveries revealed fundamental questions regarding the nature of prostate metabolism. We previously showed that prostate-specific ablation of PPARc in mice resulted in tumorigenesis and active autophagy. Here, we demonstrate control of overlapping and distinct aspects of prostate epithelial metabolism by ectopic expression of individual PPARc isoforms in PPARc knockout prostate epithelial cells. Expression and activation of either PPARc 1 or 2 reduced de novo lipogenesis and oxidative stress and mediated a switch from glucose to fatty acid oxidation through regulation of genes including Pdk4, Fabp4, Lpl, Acot1 and Cd36. Differential effects of PPARc isoforms included decreased basal cell differentiation, Scd1 expression and triglyceride fatty acid desaturation and increased tumorigenicity by PPARc1. In contrast, PPARc2 expression significantly increased basal cell differentiation, Scd1 expression and AR expression and responsiveness. Finally, in confirmation of in vitro data, a PPARc agonist versus high-fat diet (HFD) regimen in vivo confirmed that PPARc agonization increased prostatic differentiation markers, whereas HFD downregulated PPARc-regulated genes and decreased prostate differentiation. These data provide a rationale for pursuing a fundamental metabolic understanding of changes to glucose and fatty acid metabolism in benign and malignant prostatic diseases associated with systemic metabolic stress.
investigation of metabolic genes and potential metabolic therapies in benign and malignant prostatic diseases. 3, 10 The peroxisome proliferator-activated receptors (PPARs) are a family of nuclear fatty acid receptors that regulate tissuespecific cellular metabolism and differentiation and have been widely sought after therapeutic targets for a number of obesity-related metabolic diseases owing to their ability to regulate glucose and fatty acid metabolism. 11, 12 A class of PPARgamma (PPARg) agonists called thiazolidinediones (TZDs) are used in the treatment of insulin resistance and regulate a wide range of genes with tissue-specific effects. 13 Historically, PPARg has been associated with pre-adipocyte expansion and differentiation, 14 but other tissues also show a functional role for PPARg, including liver 15 and muscle. 16 We showed previously that PPARg ablation in mouse prostate causes tumorigenesis and active autophagy, 17, 18 suggesting PPARg may provide a molecular link between systemic metabolism and prostate differentiation and growth. 19 There are two isoforms of PPARg with the longer PPARg2 isoform using an alternate transcription start site containing a 30-amino acid N-terminal extension.
Our goal in this study was to garner a fundamental molecular and cellular understanding of the role of PPARg in mediating metabolic control of prostatic differentiation. Because of the importance of individual PPARg isoforms in systemic metabolism and our previous work implicating PPARg in prostate epithelial growth and differentiation, we chose to examine the potential roles of individual PPARg isoforms in mediating nutrient metabolism in the prostate, which has not been performed in any tissue. A prostatic epithelial cell line (mPrE-PPARgKO) restored with either PPARg1 or PPARg2 isoform was used to determine how each isoform might contribute to prostatic metabolism, differentiation and disease. We show, using in vitro analysis, lipidomics and in vivo animal models that PPARg isoforms control overlapping and distinct metabolic programs in prostate epithelia that lead to functional changes in glucose and lipid metabolism and that these changes are coordinate with reduced lipogenesis, increased b-oxidation and markers of basal and luminal epithelial differentiation. Furthermore, we show in animals that prostate differentiation is oppositely affected after chronic treatment with a TZD versus high-fat diet (HFD) through disparate regulation of PPARg-and its downstream genes. These data suggest, as in other tissues, that PPARg agonization may directly or indirectly modulate the nutritional supply of glucose and lipids for prostate metabolism and differentiation.
Results
Restoration of PPARc2, but not PPARc1, reverses PPARcKO-induced mouse prostatic carcinogenesis. Alternative transcription start sites and splicing produce two PPARg isoforms, so only the longer PPARg2 isoform can be knocked out individually. 20 In order to study the independent functions of PPARg1 and -g2 isoforms on prostate metabolism and differentiation, we developed a prostate epithelial cell line (mPrE-PPARgKO) with genetic knockout (KO) of both PPARg1 and -g2 isoforms from an adult PB-Cre4 tg/0 / PPARg flox/flox double-transgenic male mouse. 17 We then restored mPrE-gKO cells with mouse PPARg1 cDNA ( þ PPARg1), PPARg2 cDNA ( þ PPARg2) or an empty vector ( þ EV) as control, respectively, to create an isogenic series of cell lines for genetic and functional comparisons (see Materials and Methods).
In order to determine the effects of PPARg isoforms on tissue morphogenesis in vivo, mPrE-gKO and restored cell lines were each recombined with inductive 18-day fetal rat urogenital mesenchyme (UGM) and grafted into the kidney capsule for 2 months (Figures 1a-c) . Control mPrE-gKO þ EV cells (empty vector-transfected) regenerated highgrade mouse prostatic intraepithelial neoplasia (HGPIN) (Jiang et al. 17 ; Figure 1a ) with predominantly Ck8/Ck18 þ luminal epithelial glands and few Ck14 þ basal cells ( Figure 1d ). Upon restoration with PPARg1, large areas of Ck8/18 þ þ /Ck14 À middle or highly differentiated adenocarcinoma were observed in þ PPARg1 tissue recombinants ( Figure 1b , black star, Figure 1e ), but large fluid-filled cysts were also formed ( Figure 1b , white star). PPARg2 restoration resulted in the regeneration of Ck8/18 þ /Ck14 þ þ acini that resembled developing prostate glands without evidence of tumor formation (Figures 1c and f). Furthermore, androgen receptor (AR) expression was demonstrated in regenerated tissues by immunohistochemical staining using þ EV or þ PPARg2 cells, but not with þ PPARg1 cells (Figures 1g-i). These data indicate that restoration of PPARg2 isoform, but not PPARg1 isoform, reverses PPARg-deficient mouse prostatic carcinogenesis through an increase in Ck14 þ basal cells.
PPARc isoforms 1 and 2 differentially regulate mouse prostate benign epithelial cell differentiation as well as luminal AR expression and function. In order to confirm the in vivo restoration of basal and luminal differentiation by PPARg2 expression shown in Figure 1 , protein expression in mPrE-gKO þ EV, þ PPARg1 and þ PPARg2 cells was examined by western blot, which revealed increases in both Ck14 and AR upon expression of PPARg2 (Figure 2a ). To determine whether PPARg isoform expression increased the differentiation of basal cells in vitro, each mPrE-gKO cell line was double stained in culture for PPARg and Ck14 (Figure 2b (i-iii)). Results demonstrated that although PPARg expression in þ PPARg1 cells was increased 14% versus þ EV cells, this resulted in an insignificant change in Ck14 expression ( Figure 2b (ii versus iii)). Alternatively, and consistent with regeneration experiments in vivo (Figure 1f ), PPARg2 restoration resulted in a 15% increase in PPARg þ cells as well as a 15% increase in Ck14 þ cells (Figure 2b (iii), quantified in Figure 2c ). Interestingly, only 6-9% of the PPARg þ cells had overlapping Ck14 expression, suggesting a potential paracrine regulation of basal cell differentiation. To determine whether the increase in basal cells also resulted in increase luminal differentiation, cells were treated with dihydrotestosterone (DHT) and co-stained for AR and CK14 (Figure 2b (iv-vi)). In PPARg2-rescued cells, cells adjacent to PPARg þ cells were observed to have nuclear AR localization (Figure 2b(vi) , arrowhead). In contrast, fewer cells were found with nuclear AR localization in þ EV or þ PPARg1 cells treated with DHT ( Figure 2b (iv versus v)). To confirm increased AR responsiveness, an androgen response element (ARE)-luciferase construct was transfected in each cell line, which demonstrated that þ PPARg2 cells significantly increased AR responsiveness 3-fold, while þ PPARg1 cells had no response and mPrE-gKO þ EV cells had a 1.8-fold increase ( Figure 2d ). The results showed restoration of PPARg2 rescues and drives mouse prostate benign epithelial cell differentiation associated with AR activation.
PPARc isoforms 1 and 2 regulate both overlapping and distinct metabolic networks. In order to determine the potential molecular disparity between PPARg1-and PPARg2driven epithelial differentiation, microarrays were performed on mPrE-PPARgKO þ EV versus þ PPARg1 or þ PPARg2 cells. As outlined in Figure 3a , þ EV cells minus/plus Rosiglitazone (Rosi) were examined to eliminate PPARgindependent effects of Rosi ( Supplementary Figure 1a ). These independent effects were subtracted from results generated from comparison of þ EV versus þ PPARg1 and þ EV versus þ PPARg2 to identify PPARg-specific effects of Rosi. Using INGENUITY software (Redwood City, CA, USA) and the significance analysis of microarray (SAM) test for significance, Figure 3b displays the top networks regulated by PPARg isoforms in prostate epithelial cells. Individual genes regulated by PPARg1 and PPARg2 (top 10 up and down-regulated genes shown in Supplementary Figure 1a ) included numerous focus molecules with functions related to amino acid, carbohydrate and lipid metabolism, drug metabolism and cellular detoxification as well as inflammation and immunity.
Restoration of PPARc1 or -c2 isoforms reduces lipogenesis/oxidative stress. Microarray data analysis of PPARg isoform-regulated genes showed a strong upregulation of genes involved in fatty acid metabolism, which has been shown to reduce de novo lipogenesis in some tissues; 21 however, the influence of fatty acid metabolism on prostate differentiation has not been examined. Accordingly, western blotting revealed that PPARg1 or PPARg2 expression resulted in a decrease in lipogenic pathways (Akt, mTOR, Fasn, Acc) and oxidative stress (Cox-2) ( Figure 4a ). Flow cytometry of dihydroethidium-stained cell lines confirmed a significant reduction in reactive oxygen species (ROS) upon expression of PPARg isoforms ( Figure 4b ). These data suggest that paracrine PPARg expression satisfies the endogenous lipid needs, thereby negating the need for de novo lipogenesis.
To confirm candidate genes identified by INGENUITY software analysis, qRT-PCR plates were custom-designed for analysis of PPARg-restored cell lines. Results showed that both PPARg isoforms regulated genes involved in metabolism ( Table 1 , Section I), including the modification (Elovl4, Scd1), transport (Cd36, Lpl, Fabp4) and b-oxidation (Acsf2, Lipa, Acot1) of fatty acids. In addition, multiple genes involved in detoxification were upregulated ( Table 1 , Section II), notably including Cox-2, further confirming the decrease in ROS shown in Figure 4b . Finally, multiple markers of differentiation (Table 1 , Section III) were upregulated, notably including regulation of basal cell (Trp63, Ck14) and luminal cell (Pbsn, AR, PTEN) markers by PPARg2, confirming the changes shown in Figure 1 . These data suggest that increased fatty acid import results in a reduction in lipogenesis and oxidative stress.
PPARg isoforms differentially regulate glucose and fatty acid metabolism. One of the most interesting examples of isoform-specific changes in fatty acid modification genes was the differential regulation of Scd1, which was upregulated by PPARg2 but downregulated by PPARg1 (Table 1 , Section I).
Scd1 is an ER-resident fatty acid desaturase strongly induced by dietary saturated fat and responsible for the production of monounsaturated fatty acids (MUFAs) from 12 to 19 carbon saturated fatty acids, and has been implicated in numerous metabolic diseases. MUFAs are the preferred substrates in the synthesis of major lipid classes including phospholipids, cholesterol esters, wax esters and triglycerides. 22, 23 When various lipid classes were analyzed (phospholipids, diglycerides, triglycerides and cholesterol esters) in PPARg1 and -g2-restored mPrE-gKO cells, we found that not only were total triglyceride stearic acid levels increased, but also that the PPARg1-mediated Scd1 decrease resulted in a significantly increased abundance of stearic acid and decreased abundance of oleic acid ( Figure 4c ). As shown above, PPARg1 expression also failed to induce prostatic differentiation ( Figures 1 and 2 ), indicating that an increased availability of MUFAs through PPARg2-mediated Scd1 expression may be beneficial for normal prostate epithelial differentiation.
As for other PPARs, 21 we found using qRT-PCR that PPARg1 and -g2 also regulated glucose metabolism genes, notably increasing Pdk4 expression ( Table 1 ). Pdk4 phosphorylates and inactivates pyruvate dehydrogenase, resulting in the shunting of pyruvate toward lactate production rather than entry in the mitochondrial tricarboxylic acid (TCA) cycle. In tissues such as muscle, metabolic switching from glucose to fatty acid oxidation is mediated by increased Pdk4 expression. 24 To determine whether increased Pdk4 expression resulted in altered glucose/lactate flux, we collected conditioned media from mPrE-PPARgKO and the isoformrestored cells over a 4-day period. Results demonstrated a decrease in glucose flux in PPARg-restored cells (Figure 4d) , coordinate with the level of Pdk4 expression (Table 1) , with PPARg1 mediating the strongest upregulation of Pdk4 and decrease in glucose consumption. A significant increase in lactate production was observed in PPARg2-restored cells, indicating increased glycolytic metabolism. Furthermore, the increased glucose/lactate ratios observed in both PPARgrestored cells points to a clear shift away from glucose oxidation in the TCA cycle in favor of lactate production. Measurement of the IC50 of the glucose analog and oxidation inhibitor 2-deoxy-D-glucose (2DG) showed that mPrE-PPARgKO þ EV cells were significantly more sensitive to inhibition of glucose metabolism than their PPARg-restored counterparts (Figure 4e ), which are more likely to rely on fatty acid oxidation according to genes shown in Table 1 .
These data demonstrate that although restoration of either PPARg isoform in PPARg KO HGPIN cells decreases de novo lipogenesis and oxidative stress, only PPARg2-regulated genes induce a metabolic switch for induction of a prostatic differentiation program, potentially through disparate regulation of Scd1.
TZD or HFD treatment drives opposing effects on mouse prostate metabolism and differentiation in vivo. PPARg has been hypothesized to provide a metabolic link between obesity and tissue dysfunction. 13 In order to determine whether TZDs or obesity affect PPARg-mediated prostatic differentiation in vivo, we fed male mice a Western diet or Rosiglitazone chow for 6 months and examined their prostates for changes in morphology ( Figure 5 ) and PPARg-regulated genes ( Table 2 ). Significant increases in overall animal weight were detected following HFD treatment only (Figure 5a ). Notable increases in smooth muscle density were observed with TZD treatment (Figure 5d ), with little epithelial hyperplasia. In addition, intra-muscular adipocytes were also highly enriched in TZD-treated animals (Figure 5d , star), which made clean dissection for RNA analysis of prostate-specific genes extremely difficult. This is consistent with the deposition of intramuscular adipocytes in skeletal muscle of TZD-treated human subjects. 25 Although PPARg2 is thought of as an adipose-specific gene, we were able to demonstrate using a PPARg2-specific antibody that it is also expressed sporadically in mouse prostate luminal epithelia (Figure 5f ) as well as throughout the smooth muscle ( Figure 5b ).
As shown in Table 2 , large increases in PPARg-regulated genes were observed in TZD-treated animals. Given the Table 1 ). (d) Glucose/lactate flux analysis in mPrE-PPARgKO þ EV, þ PPARg1 or þ PPARg2 cells over 4 days (2 time points/day) demonstrated significantly decreased glucose uptake in mPrE-PPARgKO þ PPARg1 cells and significantly increased lactate secretion in mPrE-PPARgKO þ PPARg2 cells compared to þ EV cells. (e) IC50 analysis of the glucose oxidation inhibitor 2DG suggested a reliance of mPrE-PPARgKO þ EV cells on glucose in the absence of þ PPARg1 or þ PPARg2 cells, which highly regulate fatty acid transport and metabolism (see Table 1 ). *P value o0.05 increase in intraprostatic adipocytes after TZD treatment, it was unclear whether these changes were regulated in adipocytes or prostate. Therefore, immunohistochemistry was performed on metabolic proteins including Scd1, Lpl, Cd36, Fabp4 and Pdk4. Although ectopic PPARg expression was able to regulate some of the fatty acid metabolism genes in vitro (Table 1) , immunoreactivity for Fabp4 ( Supplementary  Figure 1c ), Lpl and Scd1 was low in mouse prostate and high in adjacent adipocytes, likely reflecting the strong increases in RNA expression shown in Table 2 , Section II. However, immunoreactivity for Cd36 (expressed in epithelia and stroma, Supplementary Figure 1b ) and Pdk4 (expressed in epithelia, Figure 5l -n) were strong, suggesting that these genes might be important in directly mediating the metabolism and differentiation of prostate, versus Fabp4 and Lpl, which may indirectly mediate prostate differentiation through adjacent adipocyte fatty acid metabolism.
As PPARg-regulated genes were so drastically affected in TZD-treated animals, epididymal white adipose tissue (eWAT) gene expression was also examined by qRT-PCR under normal conditions or TZD treatment and was directly compared with that of prostate ( Table 2 , row 1 versus row 2). Results are compartmentalized into genes predominantly regulated by TZD in either eWAT (I) or prostate (II) or both (III). Contrary to common perceptions of both adipose and prostate, total PPARg levels (isoforms were not discriminated by qRT-PCR) were higher in prostate than eWAT under normal feeding conditions and AR levels were equivalently expressed (contamination by adipocytes in prostates of animals fed regular chow was minimal). However, under 26 which could explain the lower levels of total PPARg in lean mouse eWAT versus prostate. Recent evidence of the molecular signature of various adipose depots could also explain the difference in PPARg-regulated genes in eWAT versus the intramuscular adipose of TZD-treated prostate, 27 which may indicate the expansion of highly metabolic brown adipose shown previously to be regulated by TZDs. 28 Other notable differences between prostate and eWAT gene expression patterns included numerous oxidative stress genes (Cat, Gsta2, Sirt5, Nox1, Nfkb2) and the triglyceridesynthesizing enzyme Dgat2, which were highly enriched in adipose versus prostate. However, a number of fatty acid metabolism (Acsf2, Adipor1, Cd36, Lpl) and differentiation Figure 5 Administration of TZD or HFD drives opposing effects on mouse prostate metabolism and differentiation in vivo. (a) Western diet-, but not TZD-fed animals significantly increased total weights by 20 g (N ¼ 3 each). (b) PPARg2 is coexpressed in prostate smooth muscle. (c-n) C57B male mice were fed control (a, f, i and l), Rosiglitazone (b, g, j and m) or Western diet chow (e, h, k and n) for 6 months. PPARg2 levels were similar in prostate epithelia after TZD treatment (f versus g) but decreased in some acini of HFD-treated animals (h, star). Intramuscular adipocytes were increased in TZD-treated animals (g, star), which also resulted in increased AR expression increased in smooth muscle (j, arrow). AR expression was decreased in HFD-treated animals (* in k) similar to qRT-PCR analysis (see Table 2 ). PDK4 expression was similar in prostate tissue of TZD-treated animals (m, * indicates adipose) and decreased in HFD-treated animals (n) (see Table 2 ) (AR, probasin) genes were equally high in prostate, including the glucose oxidation inhibitor, Pdk4, which suggests that the differentiation induced by PPARg expression shown here may represent a metabolically regulated program of prostatic differentiation in vivo.
Given the regulation of prostate differentiation by PPARg2 in mouse, we also wanted to confirm the expression of PPARg2 and some of its downstream-regulated genes in human prostate tissue. Figure 6a shows that PPARg2 is highly enriched in prostate smooth muscle and that Scd1 (upregulated by PPARg2 expression in vitro) is highly enriched in prostate basal cells (Figure 6b ). Furthermore, CD36 was expressed in both epithelia and smooth muscle (Figure 6c ), whereas PDK4 was expressed predominantly in epithelia (Figure 6d ). The compartmentalization of cellular glucose and fatty acid metabolism (Figure 6e ) suggests a model of stromal-epithelial, as well as basal-luminal interactions whose disruption by systemic metabolic disease may adversely affect the health and differentiation of prostate (Figure 6f) . These results suggest that PPARg is a major metabolic regulator in the control of mouse and human prostate differentiation.
Discussion
A recent study of the global prevalence of glycemia and diabetes demonstrated an increase from 153 million affected individuals in 1980 to 347 million in 2008, 29 which, according to epidemiological correlations, will likely have a major direct impact on prostate disease incidence. Upon maximal lipid storage capacity of white adipose tissue (WAT), peripheral tissues begin to store lipid in excess of their natural oxidative or storage capacity resulting in lipotoxicity, inflammation and eventually insulin resistance. 30 Recent evidence squarely positions prostatic diseases as sequelae of systemic metabolic dysfunction, including hyperinsulinemia, hyperglycemia and hypercholesterolemia 31 ; however, the underlying etiologies of such susceptibilities remain unknown largely because of the absence of a molecular understanding of the basic metabolic machinery governing prostatic function.
Here, we demonstrate that expression of PPARg2 drives benign prostate epithelial cell differentiation. In mouse prostate PPARg2 was expressed in both smooth muscle and epithelium (Figures 5b and f) , whereas in human prostate PPARg2 expression seems to be restricted to smooth muscle ( Figure 6a ). Stromal-epithelial interactions have long been recognized to have a role in prostate differentiation, 32 but the underlying mechanisms remain elusive. These data suggest that paracrine fatty acid metabolism may drive epithelial differentiation, resulting in decreased glucose metabolism, oxidative stress and lipogenesis (Figure 4 ). PPARg has been shown to regulate the balance between glucose and lipid oxidation in a tissue-specific manner. 33 Here, we show that TZD treatment upregulated markers of prostatic differentiation in correlation with an increase in highly metabolic smooth muscle and intramuscular adipose ( Figure 5 , Table 2 ), which also correlated with the decreased glucose flux and lipogenesis shown in PPARg-restored cells in vitro (Figure 2) .
The isoform-specific effects of PPARg have not been directly compared in any tissue. One of the most interesting genes differentially regulated by PPARg isoforms in prostate was the fatty acid desaturase Scd1. Systemic deletion of Scd1 provides protection against obesity due to reduced fatty acid and triglyceride synthesis as well as increased oxidation. 22, 23 In contrast to other tissues, SCD1 expression is high in human prostate epithelia, but its expression and role in prostate cancer has been debated. 34, 35 Moreover, PPARg2 upregulated Scd1 expression and drove basal cell differentiation ( Figure 2) , and SCD1 was shown to be predominantly restricted to the basal cell compartment of normal human prostate (Figure 6b) whereas PPARg2 was predominantly expressed in smooth muscle (Figure 6a ). As modeled in Figure 6f , these data led us to hypothesize that PPARg2-mediated import and oxidation of fatty acids may dictate prostate basal cell differentiation through increased SCD1. Tissue-specific effects of PPARg agonization have demonstrated that the upregulation of liver fatty acid and sterol synthesis in HFD-fed rats could be reversed by PPARg agonists, whereas the same HFD stimulated PPARg downregulation and lipogenesis in muscle. 13 Concordant with studies demonstrating positive effects of TZDs on HFD mouse prostates, 36, 37 we demonstrated here that chronic HFD treatment resulted in decreased androgen signaling and low-grade PIN, coordinate with decreased PPARg signaling ( Figure 5 , Table 2 ). These data suggest that an allostatic response to downregulate fatty acid import and metabolism may negatively affect prostate differentiation through metabolic switching.
Cells access and metabolize fatty acids through the activities of lipases (e.g., Lpl, Lipa), transporters (e.g., Fabp4, Cd36) and enzymes (acyl-coa synthetases, thioesterases), which supply the cell with acetyl coenzyme A (acetyl-CoA) for eventual entry into mitochondria for energy production. Alternatively, acetyl-CoA can be used as a building block for MUFA production (Scd1) and subsequently converted into triglycerides, cholesterol esters and phospholipids (Figure 6e ). The therapeutic efficacy of targeting fatty acid metabolism (synthesis, modification, transport and oxidation) has had some success, but off-target effects have limited their broad usage. 10 Similarly, more selective drugs targeting PPARg and Scd1 promising fewer side effects are being pursued. 22, 38 Future studies must be able to link changes in systemic metabolism to local metabolic changes in prostate, which mandates a deeper understanding of the fundamental metabolic infrastructure regulating prostatic differentiation and what allostatic changes may occur in response to systemic metabolic stress. The data presented here suggest that a microenvironment of PPARg2-mediated fatty acid metabolism by stroma or adipose may drive prostatic epithelial differentiation; however, under conditions of diabetes and obesity fatty acid supply may become saturated, leading to inflammation and hyperplasia in prostate disease (Figure 6f ).
Materials and Methods
Generation of cell lines, microarray studies and qRT-PCR. mPrE-PPARgKO cells were spontaneously immortalized from an adult PBCre4 tg/0 / PPARg flox/flox double-transgenic male mouse. 17 Detection of ROS. Each cell line was grown to confluence, trypsinized, washed and incubated with 1 mM Dihydroethidium (Life Technologies, Carslbad, CA, USA) for 15 min followed by three washes in PBS. Flow cytometry was then performed and results represent the average mean intensity (N ¼ 3). Statistical analysis was performed by GraphPad Prism software (La Jolla, CA, USA) using Student's unpaired t test.
Fatty acid profile (TLC/MS). Lipid class separation and fatty acid identification of cell lines were performed by the Vanderbilt Hormone Assay and Analytical Services Core (http://hormone.mc.vanderbilt.edu/). Briefly, the Folch method of lipid extraction 39 was followed by thin layer chromatography (TLC) was used to isolate triglycerides. Fatty acid analysis was performed by mass spectrometry (MS) with internal standards. Total triglycerides were normalized to protein concentration as determined by the Lowry method. Statistical analysis was performed on triplicate samples by GraphPad Prism software using one way ANOVA test.
Luciferase assay. Cells were grown to 70% confluency in 12-well culture plates and cotransfected with pRL-null (0.16 mg/well) and ARR2PB-Luciferase (1.44 mg/well) using 4 ml Lipofectamine 2000 in OptiMEM (Invitrogen, Grand Island, NY, USA). After 24 h transfection, media was replaced with 10% charcoalstripped FBS in DMEM plus or minus 10 À 8 M DHT and incubated for 24 h. At this time, cells were lysed and dual luciferase activity measured using the Dual Luciferase Reporter Assay System (Promega, Madison, WI, USA) on a Turner Biosystems 20/20 n luminometer (Promega). Results were statistically analyzed by Student's unpaired t test (N ¼ 3) using GraphPad Prism.
Western blot. Western blotting was performed as described previously. 17 Briefly, 30 mg protein was loaded on 10% SDS acrylamide gels (Life Technologies) and transferred onto PVDF membranes (Millipore, Temecula, CA, USA). The following antibodies were used for detection: mTOR, phospho-mTOR, PTEN, ACC and AKT, phospho-AKT (S473) were from Cell Signaling (1 : 1000, Danvers, MA, USA), Cox-2 (1 : 500, Millipore), AR and PPARg (1 : 250, Santa Cruz Biotechnology, Santa Cruz, CA, USA), FASN (1 : 1000, GeneTex, Irvine, CA, USA), Gapdh (1 : 1000, Abcam, Cambridge, MA, USA) and Ck14 (1 : 1000, Vector Labs, Burlingame, CA, USA). Blots were then incubated with secondary antibodies (1 : 1000, anti-mouse, anti-rabbit from GE Healthcare, Buckinghamshire, UK) for 45 min in 5% milk in TBST, washed and developed with Western Lightning Plus-ECL (Perkin Elmer, Waltham, MA, USA). ICC/IHC. ICC/IHC was performed as described previously. 17 Briefly, cells were cultured on glass chamber slides (LabTek II, Naperville, IL, USA), washed with PBS, fixed in 4% PFA for 15 min, blocked in 12% BSA for 1 h and incubated with primary antibodies (1 : 25 PPARg, Santa Cruz; 1 : 50 CK14, Vector Labs; 1 : 100 AR, Santa Cruz; 1 : 500 Ck8/18, Fitzgerald, Acton, MA, USA) in 12% BSA at 41C overnight followed by incubation with a fluorescent secondary antibody (1 : 1000, Molecular Probes, Eugene, OR, USA) for 45 min at 371C. Cells were counterstained and mounted with Dapi Vectashield (Vector Labs) and images were taken on a Zeiss Axioplan microscope. Tissues harvested from grafted (kidney capsule) or TZD-or HFD-treated mice (epididymal WAT, prostate) were fixed in 10% formalin at 41C overnight, paraffin embedded and then 5 mM sections cut for immunohistochemistry. Slides were deparaffinized, rehydrated and endogenous peroxidases blocked with 2% H 2 O 2 in methanol. Following citrate retrieval and blocking with 5% goat serum, slides were incubated at 41C overnight with the following antibodies: AR (1 : 200, Santa Cruz), PPARg2 (1 : 200, Abcam), smooth muscle actin (1 : 2000 Invitrogen), Ck14 (1 : 100), CK18 (1 : 500), PDK4 (1 : 500, ProteinTech, Chicago, IL, USA). Secondary antibodies for IHC were from Dako (Carpinteria, CA, USA) and used at 1 : 200 dilution. Secondary antibodies for IF (1 : 1000, Molecular Probes) were incubated for 45 min followed by mounting with DAPI Vectashield.
Tissue recombination. Tissue recombination was performed as described previously. 17 Briefly, 400 K of each mPrE-PPARgKO-related cell lines were recombined with 18-day fetal rat UGM and grafted in collagen into the kidney
